BRPI0809326B8 - métodos de preparação de microesfera de liberação controlada contendo exendina com camada de revestimento, composição e microesfera - Google Patents

métodos de preparação de microesfera de liberação controlada contendo exendina com camada de revestimento, composição e microesfera

Info

Publication number
BRPI0809326B8
BRPI0809326B8 BRPI0809326A BRPI0809326A BRPI0809326B8 BR PI0809326 B8 BRPI0809326 B8 BR PI0809326B8 BR PI0809326 A BRPI0809326 A BR PI0809326A BR PI0809326 A BRPI0809326 A BR PI0809326A BR PI0809326 B8 BRPI0809326 B8 BR PI0809326B8
Authority
BR
Brazil
Prior art keywords
controlled release
microsphere
active ingredient
exendin
composition
Prior art date
Application number
BRPI0809326A
Other languages
English (en)
Inventor
Lim Chae-Jin
Seol Eun-Young
Lee Hee-Yong
Choi Ho-Il
Kim Joon-Sik
Lee Ju-Han
Kim Jung-Soo
Baek Mi-Jin
Baek Mi-Young
Chae Yeon-Jin
Original Assignee
Peptron Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptron Co Ltd filed Critical Peptron Co Ltd
Publication of BRPI0809326A2 publication Critical patent/BRPI0809326A2/pt
Publication of BRPI0809326B1 publication Critical patent/BRPI0809326B1/pt
Publication of BRPI0809326B8 publication Critical patent/BRPI0809326B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

métodos de preparação de microesfera de liberação controlada contendo exendina com camada de revestimento, composição e microesfera. são proporcionadas uma composição de liberação controlada e microesferas de liberação controlada contendo exendina como ingrediente ativo e um método de preparação da mesma. mais especificamente, são proporcionados uma composição de liberação controlada contendo exendina como ingrediente ativo, um polímero biodegradável como uma viscosidade especifica e materiais de revestimento, tendo elevada biodisponibilidade e exibindo liberação sustentada do ingrediente ativo numa concentração efetiva para um certo período sem uma explosão inicial excessiva do ingrediente ativo: microesferas de liberação controlada contendo um núcleo incluindo exendina como ingrediente ativo e um polímero biodegradável e uma camada de revestimento que recobre o núcleo; e um método de preparação de microesferas de liberação controlada incluindo as etapas de misturar uma exendina, um polímero biodegradável e um solvente, remover o solvente a partir da mistura para preparar a microesferas endurecidas e revestimento sobre a superfície de cada microesfera.
BRPI0809326A 2007-03-27 2008-01-22 métodos de preparação de microesfera de liberação controlada contendo exendina com camada de revestimento, composição e microesfera BRPI0809326B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2007-0029586 2007-03-27
KR1020070029586A KR100805208B1 (ko) 2007-03-27 2007-03-27 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
PCT/KR2008/000397 WO2008117927A1 (en) 2007-03-27 2008-01-22 Composition and microsphere for controlled-release of exendin, and method of preparing the same

Publications (3)

Publication Number Publication Date
BRPI0809326A2 BRPI0809326A2 (pt) 2014-09-23
BRPI0809326B1 BRPI0809326B1 (pt) 2020-10-13
BRPI0809326B8 true BRPI0809326B8 (pt) 2021-05-25

Family

ID=39382592

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809326A BRPI0809326B8 (pt) 2007-03-27 2008-01-22 métodos de preparação de microesfera de liberação controlada contendo exendina com camada de revestimento, composição e microesfera

Country Status (16)

Country Link
US (1) US9155702B2 (pt)
EP (1) EP2134329B1 (pt)
JP (1) JP5135428B2 (pt)
KR (1) KR100805208B1 (pt)
CN (1) CN101646424B (pt)
AU (1) AU2008230297B2 (pt)
BR (1) BRPI0809326B8 (pt)
CA (1) CA2682499C (pt)
ES (1) ES2528282T3 (pt)
IL (1) IL201024A (pt)
MX (1) MX2009010280A (pt)
MY (1) MY150087A (pt)
PL (1) PL2134329T3 (pt)
RU (1) RU2463040C2 (pt)
WO (1) WO2008117927A1 (pt)
ZA (1) ZA200906381B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd BIODEGRADABLE MICRO BEADS COMPOSITION FOR CONTROLLED RELEASE OF GLUCOSE-CONTROLLED PEPTIDE AND FORMULATION THEREOF
US9292307B2 (en) 2008-07-30 2016-03-22 Kyocera Corporation User interface generation apparatus
US20100183876A1 (en) * 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
CN102370611B (zh) * 2010-08-17 2013-09-18 东莞太力生物工程有限公司 一种包含exendin-4的温度敏感型水凝胶及其注射剂
JP2014502985A (ja) * 2011-01-19 2014-02-06 ノヴォ ノルディスク アー／エス Ｇｌｐ−１粒子および組成物
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
RU2768492C2 (ru) 2011-11-18 2022-03-24 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
CN102688198B (zh) * 2012-06-19 2015-04-15 广州帝奇医药技术有限公司 多肽药物缓释微球制剂及其制备方法
WO2014124006A1 (en) * 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CN104107165B (zh) * 2013-04-17 2018-11-30 长春百益制药有限责任公司 一种艾塞那肽微球制剂、其制备方法及其应用
CN104840415B (zh) 2014-02-19 2019-03-15 香港浸会大学 含有降血糖活性成分的长效控释脂质体凝胶组合物及其制备方法
JP2017511371A (ja) * 2014-04-16 2017-04-20 シャンドン ルイ ファーマシューティカル カンパニー リミテッド エクセナチド含有組成物及びその製造方法
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
US9480640B2 (en) * 2014-09-24 2016-11-01 Hongkai Zhang Nano freeze dry process of preparation of highly bioactive agent and its method of use
CA2974715C (en) 2015-01-27 2020-05-05 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN116942677A (zh) 2015-09-21 2023-10-27 梯瓦制药国际有限责任公司 缓释奥氮平制剂
CA3001065A1 (en) 2015-10-14 2017-04-20 Xiaoxi WEI Compositions and methods for reducing ice crystal formation
WO2017107906A1 (zh) * 2015-12-22 2017-06-29 四川科伦药物研究院有限公司 一种艾塞那肽微球制剂及其制备方法
KR20190086460A (ko) * 2016-10-20 2019-07-22 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 신경보호 폴리펩티드를 중추 신경계에 전달하는 방법
CA3057438A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
KR102034872B1 (ko) * 2018-01-10 2019-10-21 주식회사 지투지바이오 콜라겐 펩타이드가 함유된 폴리카프로락톤 미립구 필러 및 그 제조방법
US12274787B2 (en) 2018-12-17 2025-04-15 G2Gbio, Inc. Sustained-release injection comprising deslorelin, and preparation method therefor
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
CN114206374A (zh) * 2019-07-29 2022-03-18 佩特通公司 用于治疗左旋多巴诱导的运动障碍或用于抑制其进展的药物组合物
BR112022001595A2 (pt) 2019-07-29 2022-03-22 Peptron Inc Composição farmacêutica para tratamento ou inibição da progressão da discinesia induzida por levodopa
WO2022153262A1 (en) 2021-01-18 2022-07-21 Anton Frenkel Pharmaceutical dosage form
CN117098529A (zh) * 2021-01-29 2023-11-21 天温轮特拉皮踢诗 初期突发释放受控的贮库组合物及其方法
US20240277654A1 (en) 2021-07-06 2024-08-22 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US5271961A (en) * 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
GB9210574D0 (en) 1992-05-18 1992-07-01 Ca Nat Research Council Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications
JPH09315975A (ja) 1995-09-28 1997-12-09 Takeda Chem Ind Ltd ２−ピペラジノン−１−酢酸誘導体の徐放剤
JP4900984B2 (ja) 1997-07-15 2012-03-21 武田薬品工業株式会社 徐放性製剤の製造法
EP1658856B1 (en) * 1999-01-14 2010-03-17 Amylin Pharmaceuticals, Inc. Exendins for glucagon suppression
CN101181236A (zh) * 1999-01-14 2008-05-21 安米林药品公司 新型exendin激动剂制剂及其给药方法
EP1246638B2 (en) * 2000-01-10 2014-07-30 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of hypertriglyceridemia
JP5160005B2 (ja) 2000-12-28 2013-03-13 武田薬品工業株式会社 徐放性製剤
KR100566573B1 (ko) 2002-04-13 2006-03-31 주식회사 펩트론 Ｌｈｒｈ 동족체를 함유하는 서방성 미립구의 제조방법
WO2004036186A2 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
PL2409707T3 (pl) * 2004-04-15 2015-08-31 Amylin Pharmaceuticals Llc Urządzenie o przedłużonym uwalnianiu na bazie polimeru
ATE424848T1 (de) * 2004-08-12 2009-03-15 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
EP1824460B1 (en) * 2004-11-10 2014-12-24 Tolmar Therapeutics, Inc. A stabilized polymeric delivery system

Also Published As

Publication number Publication date
CA2682499C (en) 2013-01-08
CN101646424A (zh) 2010-02-10
ZA200906381B (en) 2010-11-24
BRPI0809326A2 (pt) 2014-09-23
EP2134329A4 (en) 2013-07-10
JP2010522743A (ja) 2010-07-08
EP2134329B1 (en) 2015-01-07
CA2682499A1 (en) 2008-10-02
JP5135428B2 (ja) 2013-02-06
IL201024A0 (en) 2010-05-17
MY150087A (en) 2013-11-29
ES2528282T3 (es) 2015-02-06
AU2008230297B2 (en) 2010-07-29
MX2009010280A (es) 2009-10-12
PL2134329T3 (pl) 2015-07-31
AU2008230297A1 (en) 2008-10-02
IL201024A (en) 2014-01-30
BRPI0809326B1 (pt) 2020-10-13
RU2009136655A (ru) 2011-05-10
WO2008117927A1 (en) 2008-10-02
KR100805208B1 (ko) 2008-02-21
US20100136126A1 (en) 2010-06-03
US9155702B2 (en) 2015-10-13
EP2134329A1 (en) 2009-12-23
CN101646424B (zh) 2013-03-20
RU2463040C2 (ru) 2012-10-10

Similar Documents

Publication Publication Date Title
MY150087A (en) Composition and microsphere for controlled- release of exendin, and method of preparing the same
BR112013029422A2 (pt) cápsulas núcleo-revestimento
BR112012026953A8 (pt) Composto, uso de um composto, composição farmacêutica, e processo para preparar uma composição farmacêutica
BRPI0921687A8 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
ECSP10010184A (es) Producto de dispersión sólida que contiene un compuesto a base de n-aril-urea
BRPI0921583A2 (pt) Composição, uso de um sistema de solvente, processo para produzir uma composição, uso de uma composição, e, material de semente
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
AR061990A1 (es) Mejoras relacionadas a composiciones antiparasitarias
UY31698A (es) Preparacion solida de desintegracion oral
BRPI0810552A2 (pt) Composição de substância ativa, processos para preparar uma composição de substância ativa, e para preparar sementes contenda substância ativa, uso da composição de substância ativa, sementes, e, composição aquosa.
BRPI0821616B8 (pt) composição micelar de copolímero de bloco anfifílico contendo taxano e método para preparação da mesma
CL2008002076A1 (es) Compuestos derivados de ariloxazoles sustituidos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar diabetes, sindrome metabolico, dislipidemias, entre otras enfermedades.
MX2010013760A (es) Preparacion de formas farmaceuticas relajantes de musculos esqueleticos de liberacion controlada.
BRPI1006162A2 (pt) "composto,processo para preparar um composto,formulação farmacêutica,e uso de um composto".
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
CR9704A (es) Composicion farmaceutica de liberacion modificada, proceso de preparacion y metodo para emplear la misma.
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CL2007002970A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
CL2010001540A1 (es) Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-il metil)-sulfamida; proceso de preparacion de la composicion farmaceutica; composicion farmaceutica; y su uso para tratar enfermedades tales como depresion, epilepsia, entre otras.
BRPI0813374A2 (pt) Método para a modulação da taxa de liberação de ingredientes ativos microencapsulados, composições, processo para a preparação das composições, e, uso das composições.
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
CU20060153A7 (es) Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
BRPI0922714A2 (pt) composto, processo para preparar um compsoto, medicamento, uso de um composto, e, composição farmacêutica
BR112013001422A2 (pt) metodo para tratar ou previnir disturbios induzidos por l-dopa, agonista dopamina e/ou acentuador de dopamina em um individuo que necessita dos mesmos, agente, composição, uso de ou mais agentes e metodo para tratar a doença de parkinson

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/01/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF